Results of the current study have provided insight into additional molecular pathways that can be further explored to develop enhanced therapeutic modalities for retroperitoneal WDLPS and DDLPS including molecular pathways that are somewhat surprising in distinguishing WDLPS from DDLPS such as HIF-1 signaling, TGF-β signaling, and the epithelial-mesenchymal transition (EMT) pathways that are indicators of aggressive tumor behavior and metastasis. This evidence concerns the gene HIF1A and dedifferentiated liposarcoma.